Arixa Pharmaceuticals
We Develop Oral Antibiotics
hero2level.jpg

News & Publications

News & Publications

 

Arixa Pharmaceuticals Completes $8 Million Seed Funding

PALO ALTO, CA, TUES., MAY 1, 2018 


Gormley’s Take: Startups Seek to Conquer Antibiotic Market Challenges 

By BRIAN GORMLEY, The Wall Street Journal, Fri., Oct. 5, 2018 


Orally Absorbed Derivatives of the β‐Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs

By Eric M. Gordon, Matthew A. J. Duncton, and Mark A. Gallop, Journal of Medicinal Chemistry, Oct. 8, 2018


First Oral Antibiotic Booster for Four Decades Could Tackle Drug Resistance

By Gege Li, Chemistry World, Nov. 2, 2018


Arixa Pharmaceuticals Announces Publication of Seminal Paper Demonstrating First Oral Prodrug of Avibactam

Palo Alto, CA, Nov. 8, 2018


The Hunt for New Antibiotics Grows Harder as Resistance Builds

By MEGHA SATYANARAYANA, C&E News, Dec. 10, 2018